Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - metformiin vesinikkloriid, saxagliptin, dapagliflozin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - qtrilmet on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet:parandada glycaemic kontrollida, kui metformiin koos või ilma sulphonylurea (su) ja kas saxagliptin või dapagliflozin ei anna adekvaatset kontrolli glycaemic. kui juba ravitakse metformiin ja saxagliptin ja dapagliflozin.

Eesti - eesti - Ravimiamet

grindeks as - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 98tk; 850mg+50mg 28tk; 850mg+50mg 56tk

Eesti - eesti - Ravimiamet

grindeks as - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 28tk; 1000mg+50mg 56tk; 1000mg+50mg 98tk; 1000mg+50mg 196tk

Eesti - eesti - Ravimiamet

aurobindo pharma limited - metformiin - õhukese polümeerikattega tablett - 1000mg 90tk; 1000mg 180tk; 1000mg 50tk; 1000mg 60tk; 1000mg 100tk; 1000mg 20tk; 1000mg 70tk; 1000mg 40tk; 1000mg 80tk